» Articles » PMID: 19252333

Scaling Pharmacodynamics from in Vitro and Preclinical Animal Studies to Humans

Overview
Publisher Elsevier
Date 2009 Mar 3
PMID 19252333
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

An important feature of mechanism-based pharmacokinetic/pharmacodynamic (PK/PD) models is the identification of drug- and system-specific factors that determine the intensity and time-course of pharmacological effects. This provides an opportunity to integrate information obtained from in vitro bioassays and preclinical pharmacological studies in animals to anticipate the clinical and adverse responses to drugs in humans. The fact that contemporary PK/PD modeling continues to evolve and seeks to emulate systems level properties should provide enhanced capabilities to scale-up pharmacodynamic data. Critical steps in drug discovery and development, such as lead compound and first in human dose selection, may become more efficient with the implementation and further refinement of translational PK/PD modeling. In this review, we highlight fundamental principles in pharmacodynamics and the basic expectations for in vitro bioassays and traditional allometric scaling in PK/PD modeling. Discussion of PK/PD modeling efforts for recombinant human erythropoietin is also included as a case study showing the potential for advanced systems analysis to facilitate extrapolations and improve understanding of inter-species differences in drug responses.

Citing Articles

A Minimal PBPK/PD Model with Expansion-Enhanced Target-Mediated Drug Disposition to Support a First-in-Human Clinical Study Design for a FLT3L-Fc Molecule.

Hosseini I, Fleisher B, Getz J, Decalf J, Kwong M, Ovacik M Pharmaceutics. 2024; 16(5).

PMID: 38794321 PMC: 11125320. DOI: 10.3390/pharmaceutics16050660.


The Coming of Age of AI/ML in Drug Discovery, Development, Clinical Testing, and Manufacturing: The FDA Perspectives.

Niazi S Drug Des Devel Ther. 2023; 17:2691-2725.

PMID: 37701048 PMC: 10493153. DOI: 10.2147/DDDT.S424991.


Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design.

Vora L, Gholap A, Jetha K, Thakur R, Solanki H, Chavda V Pharmaceutics. 2023; 15(7).

PMID: 37514102 PMC: 10385763. DOI: 10.3390/pharmaceutics15071916.


Scaling Pharmacodynamics from Rats to Humans to Support Erythropoietin and Romiplostim Combination Therapy to Treat Erythropoietin-Resistant Anemia.

Fan X, Krzyzanski W, Liu D, Wong R, Yan X Pharmaceutics. 2023; 15(2).

PMID: 36839666 PMC: 9962863. DOI: 10.3390/pharmaceutics15020344.


Establishing Rationale for the Clinical Development of Cell Therapy Products: Consensus between Risk and Benefit.

Han S, Yim H, Jeong H, Choi S, Han S Int J Stem Cells. 2022; 16(1):16-26.

PMID: 36581365 PMC: 9978837. DOI: 10.15283/ijsc21189.


References
1.
Woo S, Jusko W . Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin. Drug Metab Dispos. 2007; 35(9):1672-8. DOI: 10.1124/dmd.107.015248. View

2.
Mager D, Wyska E, Jusko W . Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos. 2003; 31(5):510-8. DOI: 10.1124/dmd.31.5.510. View

3.
Liefaard L, Ploeger B, Molthoff C, Boellaard R, Lammertsma A, Danhof M . Population pharmacokinetic analysis for simultaneous determination of B (max) and K (D) in vivo by positron emission tomography. Mol Imaging Biol. 2005; 7(6):411-21. DOI: 10.1007/s11307-005-0022-3. View

4.
Hong Y, Mager D, Blum R, Jusko W . Population pharmacokinetic/pharmacodynamic modeling of systemic corticosteroid inhibition of whole blood lymphocytes: modeling interoccasion pharmacodynamic variability. Pharm Res. 2007; 24(6):1088-97. PMC: 4181339. DOI: 10.1007/s11095-006-9232-x. View

5.
Ito K, Asakura A, Yamada Y, Nakamura K, Sawada Y, Iga T . Prediction of the therapeutic dose for benzodiazepine anxiolytics based on receptor occupancy theory. Biopharm Drug Dispos. 1997; 18(4):293-303. DOI: 10.1002/(sici)1099-081x(199705)18:4<293::aid-bdd24>3.0.co;2-b. View